Liu Qiang, Rexiati Mulati, Yang Ying, Wang Wen-Guang, Azhati Baihetiya, Saimaiti Weilijiang, Wang Yu-Jie
Department of Urology, The First Affiliated Hospital of XinJiang Medical University, Ürümqi, China,
Med Oncol. 2014 Apr;31(4):882. doi: 10.1007/s12032-014-0882-y. Epub 2014 Feb 20.
Chemokines and their receptors are known to play important roles in tumor growth and metastasis of many malignancies. Recently, CC chemokine receptor 4 (CCR4) has been described as a prognostic marker in various tumors. However, the possible role of CCR4 in clear cell renal cell carcinoma (ccRCC) has not been well elucidated. In this study, we detected the expression of CCR4 in 53 ccRCC by immunohistochemistry and correlated it with clinicopathological parameters and prognosis. Immunohistochemistry was used to determine the expression of CCR4 in 53 ccRCC and 11 renal contusion tissue specimens. CCR4 expression between carcinoma and normal renal tissues was evaluated by χ(2) test. Correlation between CCR4 and clinicopathological data was tested by χ(2) test. Univariate survival analysis was performed by the Kaplan-Meier method, and differences among the groups were analyzed by the log-rank test. CCR4 expression in ccRCC tissue was significantly higher compared with normal renal tissue samples (χ(2) = 4.392, P = 0.036). CCR4 was correlated with the clinicopathological features including tumor stage (P = 0.009), lymph node metastasis (P = 0.003) and distant metastasis (P = 0.031). Further, CCR4 was the only dependent affecting factor in lymph node metastasis (P = 0.014). Univariate analysis showed that tumor stage, lymph node metastasis, distant metastasis and CCR4 were influential factors for poor prognosis in ccRCC patients; multivariate analysis revealed that CCR4 (P = 0.007) was the only independent risk factor for prognosis. In addition, Kaplan-Meier curve for overall survival (OS) indicated that prognosis was unfavorable for patients who had high CCR4 expression level (P = 0.010). CCR4 was correlated with tumor aggressive behavior in ccRCC. It might be involved in lymph node metastasis and have influence on patients' OS. Further research is needed to determine the potential of CCR4.
已知趋化因子及其受体在多种恶性肿瘤的肿瘤生长和转移中发挥重要作用。最近，CC趋化因子受体4（CCR4）已被描述为各种肿瘤中的一种预后标志物。然而，CCR4在透明细胞肾细胞癌（ccRCC）中的可能作用尚未得到充分阐明。在本研究中，我们通过免疫组织化学检测了53例ccRCC中CCR4的表达，并将其与临床病理参数及预后相关联。采用免疫组织化学方法测定53例ccRCC和11例肾挫伤组织标本中CCR4的表达。通过χ²检验评估癌组织与正常肾组织之间CCR4的表达情况。通过χ²检验检测CCR4与临床病理数据之间的相关性。采用Kaplan-Meier法进行单因素生存分析，并通过对数秩检验分析组间差异。与正常肾组织样本相比，ccRCC组织中CCR4的表达显著更高（χ² = 4.392，P = 0.036）。CCR4与包括肿瘤分期（P = 0.009）、淋巴结转移（P = 0.003）和远处转移（P = 0.031）等临床病理特征相关。此外，CCR4是淋巴结转移的唯一相关影响因素（P = 0.014）。单因素分析表明，肿瘤分期、淋巴结转移、远处转移和CCR4是ccRCC患者预后不良的影响因素；多因素分析显示CCR4（P = 0.007）是预后的唯一独立危险因素。此外，总生存（OS）的Kaplan-Meier曲线表明，CCR4表达水平高的患者预后不良（P = 0.010）。CCR4与ccRCC中的肿瘤侵袭行为相关。它可能参与淋巴结转移并影响患者的总生存期。需要进一步研究以确定CCR4的潜能。
